Exact Mass: 267.0596914

Exact Mass Matches: 267.0596914

Found 500 metabolites which its exact mass value is equals to given mass value 267.0596914, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Adenosine

(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

C10H13N5O4 (267.09674980000005)

Adenosine is a ribonucleoside composed of a molecule of adenine attached to a ribofuranose moiety via a beta-N(9)-glycosidic bond. It has a role as an anti-arrhythmia drug, a vasodilator agent, an analgesic, a human metabolite and a fundamental metabolite. It is a purines D-ribonucleoside and a member of adenosines. It is functionally related to an adenine. The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole] and [regadenson]. Adenosine is also indicated in the treatment of supraventricular tachycardia. Adenosine was granted FDA approval on 30 October 1989. Adenosine is a metabolite found in or produced by Escherichia coli (strain K12, MG1655). Adenosine is an Adenosine Receptor Agonist. The mechanism of action of adenosine is as an Adenosine Receptor Agonist. Adenosine is a natural product found in Smilax bracteata, Mikania laevigata, and other organisms with data available. Adenosine is a ribonucleoside comprised of adenine bound to ribose, with vasodilatory, antiarrhythmic and analgesic activities. Phosphorylated forms of adenosine play roles in cellular energy transfer, signal transduction and the synthesis of RNA. Adenosine is a nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. For instance, adenosine plays an important role in energy transfer - as adenosine triphosphate (ATP) and adenosine diphosphate (ADP). It also plays a role in signal transduction as cyclic adenosine monophosphate, cAMP. Adenosine itself is both a neurotransmitter and potent vasodilator. When administered intravenously, adenosine causes transient heart block in the AV node. Because of the effects of adenosine on AV node-dependent supraventricular tachycardia, adenosine is considered a class V antiarrhythmic agent. Adenosine is a metabolite found in or produced by Saccharomyces cerevisiae. A nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. See also: Adenosine; Niacinamide (component of); Adenosine; Glycerin (component of); Adenosine; ginsenosides (component of) ... View More ... Adenosine is a nucleoside that is composed of adenine and D-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. For instance, adenosine plays an important role in energy transfer as adenosine triphosphate (ATP) and adenosine diphosphate (ADP). It also plays a role in signal transduction as cyclic adenosine monophosphate (cAMP). Adenosine itself is both a neurotransmitter and potent vasodilator. When administered intravenously adenosine causes transient heart block in the AV node. Due to the effects of adenosine on AV node-dependent supraventricular tachycardia, adenosine is considered a class V antiarrhythmic agent. Overdoses of adenosine intake (as a drug) can lead to several side effects including chest pain, feeling faint, shortness of breath, and tingling of the senses. Serious side effects include a worsening dysrhythmia and low blood pressure. When present in sufficiently high levels, adenosine can act as an immunotoxin and a metabotoxin. An immunotoxin disrupts, limits the function, or destroys immune cells. A metabotoxin is an endogenous metabolite that causes adverse health effects at chronically high levels. Chronically high levels of adenosine are associated with adenosine deaminase deficiency. Adenosine is a precursor to deoxyadenosine, which is a precursor to dATP. A buildup of dATP in cells inhibits ribonucleotide reductase and prevents DNA synthesis, so cells are unable to divide. Since developing T cells and B cells are some of the most mitotically active cells, they are unable to divide and propagate to respond to immune challenges. High levels of deoxyadenosine also lead to an increase in S-adenosylhomocysteine, which is toxic to immature lymphocytes. Adenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a beta-N9-glycosidic bond. [Wikipedia]. Adenosine is found in many foods, some of which are borage, japanese persimmon, nuts, and barley. COVID info from PDB, Protein Data Bank, COVID-19 Disease Map, clinicaltrial, clinicaltrials, clinical trial, clinical trials A ribonucleoside composed of a molecule of adenine attached to a ribofuranose moiety via a beta-N(9)-glycosidic bond. Adenosine. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=58-61-7 (retrieved 2024-06-29) (CAS RN: 58-61-7). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0). Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation[1][2]. Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation[1][2]. Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation[1][2].

Deoxyguanosine

2-amino-9-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one

C10H13N5O4 (267.09674980000005)

Deoxyguanosine, also known as dG, belongs to the class of organic compounds known as purine 2-deoxyribonucleosides. Purine 2-deoxyribonucleosides are compounds consisting of a purine linked to a ribose which lacks a hydroxyl group at position 2‚Äô. Deoxyguanosine is a nucleoside consisting of the base guanine and the sugar deoxyribose. Deoxyguanosine is one of the four deoxyribonucleosides that make up DNA. Deoxyguanosine exists in all living species, ranging from bacteria to plants to humans. Deoxyguanosine participates in a number of enzymatic reactions. In particular, deoxyguanosine can be biosynthesized from 2-deoxyguanosine 5-monophosphate through the enzyme known as cytosolic purine 5-nucleotidase. In addition, deoxyguanosine can be converted into 2-deoxyguanosine 5-monophosphate (dGMP); which is mediated by the enzyme deoxyguanosine kinase. Deoxyguanosine is involved in the rare, inherited metabolic disorder called the purine nucleoside phosphorylase deficiency (PNP deficiency). In particular PNP deficiency is characterized by elevated levels of dGTP (deoxyguanosine triphosphate). PNP accounts for approximately 4\\\\% of patients with severe combined immunodeficiency (PMID: 1931007). PNP-deficient patients suffer from recurrent infections, usually beginning in the first year of life. Two thirds of patients have evidence of neurologic disorders with spasticity, developmental delay and mental retardation. Deoxyguanosine can be converted to 8-hydroxy-deoxyguanosine (8-OHdG) due to hydroxyl radical attack at the C8 of guanine. 8-hydroxy-deoxyguanosine is a sensitive marker of the DNA damage This damage, if left unrepaired, has been proposed to contribute to mutagenicity and cancer promotion. Isolated from plants, e.g. Phaseolus vulgaris (kidney bean) COVID info from COVID-19 Disease Map KEIO_ID D057; [MS2] KO008942 KEIO_ID D057 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS 2’-Deoxyguanosine (Deoxyguanosine) is a purine nucleoside with a variety of biological activities. 2’-Deoxyguanosine can induce DNA division in mouse thymus cells. 2’-Deoxyguanosine is a potent cell division inhibitor in plant cells[1][2][3]. 2'-Deoxyguanosine (Deoxyguanosine) is deoxyguanosine.

Sulfisoxazole

4-amino-N-(dimethyl-1,2-oxazol-5-yl)benzene-1-sulfonamide

C11H13N3O3S (267.06775880000004)

Sulfisoxazole is only found in individuals that have used or taken this drug. It is a short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms. [PubChem]Sulfisoxazole is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid. CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3072; ORIGINAL_PRECURSOR_SCAN_NO 3068 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6520; ORIGINAL_PRECURSOR_SCAN_NO 6519 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3077; ORIGINAL_PRECURSOR_SCAN_NO 3073 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6493; ORIGINAL_PRECURSOR_SCAN_NO 6491 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6549; ORIGINAL_PRECURSOR_SCAN_NO 6547 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3096; ORIGINAL_PRECURSOR_SCAN_NO 3094 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3126; ORIGINAL_PRECURSOR_SCAN_NO 3125 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6542; ORIGINAL_PRECURSOR_SCAN_NO 6539 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6522; ORIGINAL_PRECURSOR_SCAN_NO 6521 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6555; ORIGINAL_PRECURSOR_SCAN_NO 6553 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3083; ORIGINAL_PRECURSOR_SCAN_NO 3080 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3067; ORIGINAL_PRECURSOR_SCAN_NO 3065 J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01E - Sulfonamides and trimethoprim > J01EB - Short-acting sulfonamides S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AB - Sulfonamides C254 - Anti-Infective Agent > C29739 - Sulfonamide Anti-Infective Agent D000890 - Anti-Infective Agents > D013424 - Sulfanilamides CONFIDENCE standard compound; INTERNAL_ID 1013 Sulfisoxazole (Sulfafurazole) is an orally active endothelin receptor antagonist with IC50 values of 0.60 μM and 22 μM against endothelin receptor A and endothelin receptor B, respectively. Sulfisoxazole is a sulfonamide antibacterial agent with an oxazole substituent. Sulfisoxazole inhibits breast cancer exosome release by targeting endothelin receptor A[1][2].

OXYCARBOXIN

1,4-Oxathiin-3-carboxamide,5,6-dihydro-2-methyl-N-phenyl-, 4,4-dioxide

C12H13NO4S (267.05652580000003)

A substituted aniline that is aniline in which one of the hydrogens attached to the nitrogen atom by a (2-methyl-4,4-dioxido-5,6-dihydro-1,4-oxathiin-3-yl)carbonyl group. CONFIDENCE standard compound; INTERNAL_ID 1027; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7124; ORIGINAL_PRECURSOR_SCAN_NO 7121 CONFIDENCE standard compound; INTERNAL_ID 1027; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3210; ORIGINAL_PRECURSOR_SCAN_NO 3208 CONFIDENCE standard compound; INTERNAL_ID 1027; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3197; ORIGINAL_PRECURSOR_SCAN_NO 3195 CONFIDENCE standard compound; INTERNAL_ID 1027; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7117; ORIGINAL_PRECURSOR_SCAN_NO 7114 CONFIDENCE standard compound; INTERNAL_ID 1027; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3208; ORIGINAL_PRECURSOR_SCAN_NO 3207 CONFIDENCE standard compound; INTERNAL_ID 1027; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7096; ORIGINAL_PRECURSOR_SCAN_NO 7091 CONFIDENCE standard compound; INTERNAL_ID 1027; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3211; ORIGINAL_PRECURSOR_SCAN_NO 3209 CONFIDENCE standard compound; INTERNAL_ID 1027; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3204; ORIGINAL_PRECURSOR_SCAN_NO 3202 CONFIDENCE standard compound; INTERNAL_ID 1027; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3196; ORIGINAL_PRECURSOR_SCAN_NO 3194 CONFIDENCE standard compound; INTERNAL_ID 1027; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7129; ORIGINAL_PRECURSOR_SCAN_NO 7127

Zidovudine

1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione

C10H13N5O4 (267.09674980000005)

A dideoxynucleoside compound in which the 3-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem] J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AF - Nucleoside and nucleotide reverse transcriptase inhibitors C471 - Enzyme Inhibitor > C1589 - Reverse Transcriptase Inhibitor > C97452 - Nucleoside Reverse Transcriptase Inhibitor D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D018894 - Reverse Transcriptase Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D009676 - Noxae > D000963 - Antimetabolites > D015224 - Dideoxynucleosides D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors C254 - Anti-Infective Agent > C281 - Antiviral Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI), widely used to treat HIV infection. Zidovudine increases CRISPR/Cas9-mediated editing frequency.

S-Ribosylhomocysteine

S-(5-Deoxy-D-ribos-5-yl)-L-homocysteine

C9H17NO6S (267.07765420000004)

S-(5-deoxy-beta-D-ribos-5-yl)-L-homocysteine is an S-(5-deoxy-D-ribos-5-yl)-L-homocysteine in which the anomeric centre has beta-configuration. It has a role as an Escherichia coli metabolite. It is functionally related to a L-homocysteine.

Neuraminic acid

(2S,4S,5R,6R)-5-amino-2,4-dihydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid

C9H17NO8 (267.0954122)

Neuraminic acids are the commonest sialic acids in nature. Most sialic acids on gangliosides share a core neuraminic acid (Neu) structure and are N-acylated at the C-5 position with either an N-acetyl or an N-glycolyl group (giving Neu5Ac or Neu5Gc, respectively). It was originally thought that unsubstituted glycosidically linked Neu did not occur in nature. However, there have been several reports suggesting its presence in gangliosides and more recently in mucin-type glycoproteins. The N- or O-substituted derivatives of neuraminic acid are collectively known as sialic acids, the predominant one being N-acetylneuraminic acid. The amino group bears either an acetyl or a glycolyl group. The hydroxyl substituents may vary considerably: acetyl, lactyl, methyl, sulfate and phosphate groups have been found. Sialic acids are found widely distributed in animal tissues. Sialic acid rich glycoproteins bind selectin in humans and other organisms. Cancer cells that can metastasize often have a lot of sialic acid rich glycoproteins. This helps these late stage cancer cells enter the blood stream. (PMID: 11884388) [HMDB] Neuraminic acids are the commonest sialic acids in nature. Most sialic acids on gangliosides share a core neuraminic acid (Neu) structure and are N-acylated at the C-5 position with either an N-acetyl or an N-glycolyl group (giving Neu5Ac or Neu5Gc, respectively). It was originally thought that unsubstituted glycosidically linked Neu did not occur in nature. However, there have been several reports suggesting its presence in gangliosides and more recently in mucin-type glycoproteins. The N- or O-substituted derivatives of neuraminic acid are collectively known as sialic acids, the predominant one being N-acetylneuraminic acid. The amino group bears either an acetyl or a glycolyl group. The hydroxyl substituents may vary considerably: acetyl, lactyl, methyl, sulfate and phosphate groups have been found. Sialic acids are found widely distributed in animal tissues. Sialic acid rich glycoproteins bind selectin in humans and other organisms. Cancer cells that can metastasize often have a lot of sialic acid rich glycoproteins. This helps these late stage cancer cells enter the blood stream. (PMID: 11884388).

Miserotoxin

ZINC01531158

C9H17NO8 (267.0954122)

A beta-D-glucoside having 3-nitropropyl as the anomeric alkyl group.

Prinomide

1-Methyl-beta-oxo-alpha-(phenylcarbamoyl)-2-pyrrolepropionitrile 2-(N,N-bis(2-hydroxyethyl)amino)ethanol (1:1)salt

C15H13N3O2 (267.1007718)

C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic

Chlornaphazine

N,N-BIS(2-CHLOROETHYL)-2-NAPHTHYLAMINE

C14H15Cl2N (267.058149)

D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D009588 - Nitrogen Mustard Compounds C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent

Tiadinil

C11H10ClN3OS (267.023308)

7H-Dibenzo[c,g]carbazole

C20H13N (267.10479380000004)

D009676 - Noxae > D002273 - Carcinogens

2-METHYL-1-NITROANTHRAQUINONE

2-Methyl-1-nitro-9,10-anthraquinone

C15H9NO4 (267.0531554)

2-Amino-4-oxo-6-(1',2'-dioxoprolyl)-7,8-dihydroxypteridine

1-(2-amino-7,8-dihydroxy-4-oxo-3,4,7,8-tetrahydropteridin-6-yl)propane-1,2-dione

C9H9N5O5 (267.0603664)

This compound It is a byproduct of 6-pyruvoyltetrahydropterin synthase (EC 4.2.3.12), and associated with 6-Pyruvoyltetrahydropterin synthase deficiency (an autosomal recessive disorder that causes malignant hyperphenylalaninemia due to tetrahydrobiopterin deficiency). (Wikipedia). This compound It is a byproduct of 6-pyruvoyltetrahydropterin synthase (EC 4.2.3.12), and associated with 6-Pyruvoyltetrahydropterin synthase deficiency (an autosomal recessive disorder that causes malignant hyperphenylalaninemia due to tetrahydrobiopterin deficiency). [HMDB]

4-Nitrososulfamethoxazole

C10H9N3O4S (267.0313754)

D000890 - Anti-Infective Agents > D013424 - Sulfanilamides

Sulfamoxole

4-amino-N-(dimethyl-1,3-oxazol-2-yl)benzene-1-sulfonamide

C11H13N3O3S (267.06775880000004)

Sulfamoxole is only found in individuals that have used or taken this drug. It is a sulfonamide antibacterial. Sulfamoxole is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. This enzyme is needed for the proper processing of para-aminobenzoic acid (PABA) which is essential for folic acid synthesis. The inhibited reaction is necessary in these organisms for the synthesis of folic acid. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01E - Sulfonamides and trimethoprim > J01EC - Intermediate-acting sulfonamides C254 - Anti-Infective Agent > C29739 - Sulfonamide Anti-Infective Agent D000890 - Anti-Infective Agents > D013424 - Sulfanilamides

Vidarabine

(2R,3S,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

C10H13N5O4 (267.09674980000005)

A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the vaccinia VIRUS and varicella zoster virus. [PubChem] J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AB - Nucleosides and nucleotides excl. reverse transcriptase inhibitors S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AD - Antivirals D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C471 - Enzyme Inhibitor > C29575 - DNA Polymerase Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent D009676 - Noxae > D000963 - Antimetabolites Vidarabine (Ara-A) an antiviral agent which is active against herpes simplex and varicella zoster viruses[1][2]. Vidarabine has IC50s of 9.3 μg/ml for HSV-1 and 11.3 μg/ml for HSV-2[2]. Vidarabine also has anti-orthopoxvirus activity[3]. Vidarabine (Ara-A) an antiviral agent which is active against herpes simplex and varicella zoster viruses[1][2]. Vidarabine has IC50s of 9.3 μg/ml for HSV-1 and 11.3 μg/ml for HSV-2[2]. Vidarabine also has anti-orthopoxvirus activity[3]. Vidarabine (Ara-A) an antiviral agent which is active against herpes simplex and varicella zoster viruses[1][2]. Vidarabine has IC50s of 9.3 μg/ml for HSV-1 and 11.3 μg/ml for HSV-2[2]. Vidarabine also has anti-orthopoxvirus activity[3].

N-(1-Deoxy-1-fructosyl)serine

(2S)-3-hydroxy-2-({[(3S,4S,5R)-2,3,4-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methyl}amino)propanoic acid

C9H17NO8 (267.0954122)

Fructose aminoacids are naturally occurring compounds derived from D-fructose and L-aminoacids. They are amadori products resulting from sugar-aminoacid interactions in food products, especially cooked foods [CCD] N-(1-Deoxy-1-fructosyl)serine is classified as a Natural Food Constituent (code WA) in the DFC.

Guanidine, (4-chloro-3-methoxy-1-oxo-1H-2-benzopyran-7-yl)-

C11H10ClN3O3 (267.041066)

2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one

C16H13NO3 (267.0895388)

C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C69145 - Mitogen-Activated Protein Kinase Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2149 - Mitogen-Activated Protein Kinase Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors PD98059 is a potent and selective MEK inhibitor with an IC50 of 5 μM. PD98059 binds to the inactive form of MEK, thereby preventing the activation of MEK1 (IC50 of 2-7 μM) and MEK2 (IC50 of 50 μM) by upstream kinases. PD98059 is a ERK1/2 signaling inhibitor. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR), and suppresses TCDD binding (IC50 of 4 μM) and AHR transformation (IC50 of 1 μM). PD98059 also inhibits Mycobacterium bovis Bacillus CalmetteGuerin (BCG)-induced autophagy[1][2][3].

3'-Azido-3'-deoxythymidine, 98\%

1-[4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione

C10H13N5O4 (267.09674980000005)

8-Oxo-2'-deoxyadenosine

6-amino-9-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-8,9-dihydro-7H-purin-8-one

C10H13N5O4 (267.09674980000005)

(S)-2-Amino-5-((4-nitrophenyl)amino)-5-oxopentanoic acid

C11H13N3O5 (267.0855168)

9-Arabinofuranosyladenine

2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

C10H13N5O4 (267.09674980000005)

3'-C-Ethynylcytidine

4-amino-1-[4-ethynyl-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one

C11H13N3O5 (267.0855168)

Formycin A

2-{7-amino-2H-pyrazolo[4,3-d]pyrimidin-3-yl}-5-(hydroxymethyl)oxolane-3,4-diol

C10H13N5O4 (267.09674980000005)

Miserotoxin

2-(hydroxymethyl)-6-(3-nitropropoxy)oxane-3,4,5-triol

C9H17NO8 (267.0954122)

3-[(2-Benzyl-3-sulfanylpropanoyl)amino]propanoic acid

3-[(2-Benzyl-1-hydroxy-3-sulphanylpropylidene)amino]propanoic acid

C13H17NO3S (267.0929092)

Sulfatroxazole

4-Amino-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzene-1-sulphonamide

C11H13N3O3S (267.06775880000004)

N-acetylglutamyl-phosphate

4-[(1-Oxidoethylidene)amino]-5-oxo-5-(phosphonooxy)pentanoic acid

C7H10NO8P (267.014403)

N-acetylglutamyl-phosphate is soluble (in water) and a moderately acidic compound (based on its pKa). N-acetylglutamyl-phosphate can be found in a number of food items such as tronchuda cabbage, guava, sweet rowanberry, and acorn, which makes N-acetylglutamyl-phosphate a potential biomarker for the consumption of these food products.

Cenobamate

[(1R)-1-(2-Chlorophenyl)-2-(2H-1,2,3,4-tetrazol-2-yl)ethoxy]carboximidate

C10H10ClN5O2 (267.052299)

NSC102811

C10H13N5O4 (267.09674980000005)

U 68204

C13H17NO3S (267.0929092)

ICM 0201

STF-62247

N-(3-methylphenyl)-4-(4-pyridinyl)-2-thiazolamine

C15H13N3S (267.0830138)

sulfamoxol

4-amino-N-(dimethyl-1,3-oxazol-2-yl)benzene-1-sulfonamide

C11H13N3O3S (267.06775880000004)

J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01E - Sulfonamides and trimethoprim > J01EC - Intermediate-acting sulfonamides A sulfonamide-based antibacterial agent where 4-aminobenzenesulfonic acid and 4,5-dimethyl-1,3-oxazol-2-amine have combined to form the sulfonamide bond. C254 - Anti-Infective Agent > C29739 - Sulfonamide Anti-Infective Agent D000890 - Anti-Infective Agents > D013424 - Sulfanilamides CONFIDENCE standard compound; INTERNAL_ID 8; HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu) Flow Injection; CONFIDENCE Reference Standard (Level 1); HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu) CONFIDENCE Reference Standard (Level 1); HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu); Flow Injection CONFIDENCE Reference Standard (Level 1); HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu) CONFIDENCE standard compound; INTERNAL_ID 1019

Zidovudine

C10H13N5O4 (267.09674980000005)

J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AF - Nucleoside and nucleotide reverse transcriptase inhibitors C471 - Enzyme Inhibitor > C1589 - Reverse Transcriptase Inhibitor > C97452 - Nucleoside Reverse Transcriptase Inhibitor D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D018894 - Reverse Transcriptase Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D009676 - Noxae > D000963 - Antimetabolites > D015224 - Dideoxynucleosides D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors C254 - Anti-Infective Agent > C281 - Antiviral Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; EAWAG_UCHEM_ID 3287 Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI), widely used to treat HIV infection. Zidovudine increases CRISPR/Cas9-mediated editing frequency.

Adenosine

C10H13N5O4 (267.09674980000005)

COVID info from PDB, Protein Data Bank, COVID-19 Disease Map, clinicaltrial, clinicaltrials, clinical trial, clinical trials D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058913 - Purinergic Agonists D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents C - Cardiovascular system > C01 - Cardiac therapy Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Formula(Parent): C10H13N5O4; Bottle Name:Adenosine; PRIME Parent Name:Adenosine; PRIME in-house No.:0040 R0018, Purines MS2 deconvoluted using MS2Dec from all ion fragmentation data, MetaboLights identifier MTBLS1040; OIRDTQYFTABQOQ_STSL_0143_Adenosine_0500fmol_180430_S2_LC02_MS02_33; Spectrum acquired as described in Naz et al 2017 PMID 28641411. Preparation and submission to MassBank of North America by Chaleckis R. and Tada I. MS2 deconvoluted using CorrDec from all ion fragmentation data, MetaboLights identifier MTBLS1040; Spectrum acquired as described in Naz et al 2017 PMID 28641411. Preparation and submission to MassBank of North America by Chaleckis R. and Tada I. relative retention time with respect to 9-anthracene Carboxylic Acid is 0.113 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.109 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.097 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.096 Acquisition and generation of the data is financially supported by the Max-Planck-Society IPB_RECORD: 2621; CONFIDENCE confident structure Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation[1][2]. Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation[1][2]. Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation[1][2].

Rhamnopterin

C10H13N5O4 (267.09674980000005)

relative retention time with respect to 9-anthracene Carboxylic Acid is 0.055 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.054

sulfisoxazole

C11H13N3O3S (267.06775880000004)

J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01E - Sulfonamides and trimethoprim > J01EB - Short-acting sulfonamides S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AB - Sulfonamides C254 - Anti-Infective Agent > C29739 - Sulfonamide Anti-Infective Agent D000890 - Anti-Infective Agents > D013424 - Sulfanilamides Sulfisoxazole (Sulfafurazole) is an orally active endothelin receptor antagonist with IC50 values of 0.60 μM and 22 μM against endothelin receptor A and endothelin receptor B, respectively. Sulfisoxazole is a sulfonamide antibacterial agent with an oxazole substituent. Sulfisoxazole inhibits breast cancer exosome release by targeting endothelin receptor A[1][2].

2-Deoxyguanosine

C10H13N5O4 (267.09674980000005)

A purine 2-deoxyribonucleoside having guanine as the nucleobase. COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS 2’-Deoxyguanosine (Deoxyguanosine) is a purine nucleoside with a variety of biological activities. 2’-Deoxyguanosine can induce DNA division in mouse thymus cells. 2’-Deoxyguanosine is a potent cell division inhibitor in plant cells[1][2][3]. 2'-Deoxyguanosine (Deoxyguanosine) is deoxyguanosine.

Deoxyguanosine

2-Deoxyguanosine

C10H13N5O4 (267.09674980000005)

2’-Deoxyguanosine (Deoxyguanosine) is a purine nucleoside with a variety of biological activities. 2’-Deoxyguanosine can induce DNA division in mouse thymus cells. 2’-Deoxyguanosine is a potent cell division inhibitor in plant cells[1][2][3]. 2'-Deoxyguanosine (Deoxyguanosine) is deoxyguanosine.

8-oxo-7,8-Dihydro-2-deoxyadenosine

C10H13N5O4 (267.09674980000005)

MMV687145

C12H17N3O2S (267.1041422)

MMV688557

C12H13NO2S2 (267.0387678)

ADENOSINE 2,3-CYCLIC MONOPHOSPHATE

C10H13N5O4 (267.09674980000005)

Adenosine (not validated)

C10H13N5O4 (267.09674980000005)

Annotation level-2

N2-(4-Nitrophenyl)-L-glutamine

C11H13N3O5 (267.0855168)

CONFIDENCE standard compound; INTERNAL_ID 389; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2776; ORIGINAL_PRECURSOR_SCAN_NO 2775 CONFIDENCE standard compound; INTERNAL_ID 389; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2670; ORIGINAL_PRECURSOR_SCAN_NO 2668 CONFIDENCE standard compound; INTERNAL_ID 389; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2770; ORIGINAL_PRECURSOR_SCAN_NO 2767 CONFIDENCE standard compound; INTERNAL_ID 389; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2698; ORIGINAL_PRECURSOR_SCAN_NO 2695 CONFIDENCE standard compound; INTERNAL_ID 389; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2719; ORIGINAL_PRECURSOR_SCAN_NO 2717 CONFIDENCE standard compound; INTERNAL_ID 389; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2769; ORIGINAL_PRECURSOR_SCAN_NO 2768 CONFIDENCE standard compound; INTERNAL_ID 389; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5877; ORIGINAL_PRECURSOR_SCAN_NO 5874 CONFIDENCE standard compound; INTERNAL_ID 389; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5889; ORIGINAL_PRECURSOR_SCAN_NO 5886 CONFIDENCE standard compound; INTERNAL_ID 389; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5895; ORIGINAL_PRECURSOR_SCAN_NO 5893 CONFIDENCE standard compound; INTERNAL_ID 389; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5903; ORIGINAL_PRECURSOR_SCAN_NO 5901 CONFIDENCE standard compound; INTERNAL_ID 389; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5926; ORIGINAL_PRECURSOR_SCAN_NO 5924 CONFIDENCE standard compound; INTERNAL_ID 389; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5926; ORIGINAL_PRECURSOR_SCAN_NO 5925

Adenosine; LC-tDDA; CE10

C10H13N5O4 (267.09674980000005)

Adenosine; LC-tDDA; CE20

C10H13N5O4 (267.09674980000005)

Adenosine; LC-tDDA; CE30

C10H13N5O4 (267.09674980000005)

Adenosine; LC-tDDA; CE40

C10H13N5O4 (267.09674980000005)

8-Oxo-deoxyadenosine

C10H13N5O4 (267.09674980000005)

7-Deazadeoxyxanthosine

C11H13N3O5 (267.0855168)

3-Hydroxy-7-aminonitrazepam

C15H13N3O2 (267.1007718)

Vidarabine

C10H13N5O4 (267.09674980000005)

J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AB - Nucleosides and nucleotides excl. reverse transcriptase inhibitors S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AD - Antivirals D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C471 - Enzyme Inhibitor > C29575 - DNA Polymerase Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent D009676 - Noxae > D000963 - Antimetabolites Vidarabine (Ara-A) an antiviral agent which is active against herpes simplex and varicella zoster viruses[1][2]. Vidarabine has IC50s of 9.3 μg/ml for HSV-1 and 11.3 μg/ml for HSV-2[2]. Vidarabine also has anti-orthopoxvirus activity[3]. Vidarabine (Ara-A) an antiviral agent which is active against herpes simplex and varicella zoster viruses[1][2]. Vidarabine has IC50s of 9.3 μg/ml for HSV-1 and 11.3 μg/ml for HSV-2[2]. Vidarabine also has anti-orthopoxvirus activity[3]. Vidarabine (Ara-A) an antiviral agent which is active against herpes simplex and varicella zoster viruses[1][2]. Vidarabine has IC50s of 9.3 μg/ml for HSV-1 and 11.3 μg/ml for HSV-2[2]. Vidarabine also has anti-orthopoxvirus activity[3].

3-Deoxyguanosine

C10H13N5O4 (267.09674980000005)

3′-Deoxyguanosine (Guanosine, 3'-deoxy-) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1].

2-Amino-4-oxo-6-(1,2-dioxoprolyl)-7,8-dihydroxypteridine

C9H9N5O5 (267.0603664)

PD 98059

2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one

C16H13NO3 (267.0895388)

5-benzyl-5-(pyridin-3-yl)imidazolidine-2,4-dione

C15H13N3O2 (267.1007718)

2-NITRO-4-TRIFLUOROMETHYL-BIPHENYL

C13H8F3NO2 (267.0507104)

N-(2-Methylphenyl)-4-(3-pyridinyl)-1,3-thiazol-2-amine

C15H13N3S (267.0830138)

3-(3,4-DICHLOROPHENOXY)BENZYLAMINE

C13H11Cl2NO (267.02176560000004)

Methyl 3-Amino-5-(4-chlorophenyl)thiophene-2-carboxylate

C12H10ClNO2S (267.01207500000004)

9-ALPHA-RIBOFURANOSYLADENINE

Dexfenfluramine hydrochloride

(S)-fenfluramine hydrochloride

C12H17ClF3N (267.10015480000004)

D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist C78272 - Agent Affecting Nervous System > C29728 - Anorexiant

1-(2,4-DINITROPHENYL)PYRIDINIUMCHLORIDE

C13H11Cl2NO (267.02176560000004)

8-methyl-2-(5-methylfuran-2-yl)quinoline-4-carboxylic acid

C16H13NO3 (267.0895388)

4-{[(2E)-3-Phenyl-2-propenoyl]amino}benzoic acid

C16H13NO3 (267.0895388)

furtrethonium iodide

C8H14INO (267.0120104)

(S)-Benzyl 2-azido-2-phenylethanoate

C15H13N3O2 (267.1007718)

(4-BROMO-3-METHYLPHENYL)(PYRROLIDIN-1-YL)METHANONE

C12H14BrNO (267.02586940000003)

1-(4-Chlorophenyl)-2-methyl-2-morpholinopropan-1-one

C14H18ClNO2 (267.1025998)

N-(2-Butyl-benzofuran-5-yl)-methanesulfonamide

C13H17NO3S (267.0929092)

3-Quinolinecarboxylic acid, 5-chloro-1,2-dihydro-4-hydroxy-1-Methyl-2-oxo-, Methyl ester

C12H10ClNO4 (267.029833)

NSC697923

C11H9NO5S (267.0201424)

4-(2-fluorophenoxy)pyridine-2-carboximidamide,hydrochloride

C12H11ClFN3O (267.0574638)

4-(4-fluorophenoxy)pyridine-2-carboximidamide,hydrochloride

C12H11ClFN3O (267.0574638)

4-(3-fluorophenoxy)pyridine-2-carboximidamide,hydrochloride

C12H11ClFN3O (267.0574638)

6-(2-chlorophenyl)pyridine-2-carboximidamide,hydrochloride

C12H11Cl2N3 (267.03299860000004)

6-(3-chlorophenyl)pyridine-2-carboximidamide,hydrochloride

C12H11Cl2N3 (267.03299860000004)

6-(4-chlorophenyl)pyridine-2-carboximidamide,hydrochloride

C12H11Cl2N3 (267.03299860000004)

2-[(4-BROMOPHENYL)METHYL]HEXAHYDRO-1H-AZEPINE

C13H18BrN (267.0622528)

3-AMINO-3-(2-FLUORO-5-TRIFLUOROMETHOXY-PHENYL)-PROPIONIC ACID

C10H9F4NO3 (267.0518532)

3-AMINO-3-(3-CHLORO-5-TRIFLUOROMETHYL-PHENYL)-PROPIONIC ACID

C10H9ClF3NO2 (267.027388)

3-AMINO-3-(4-CHLORO-3-TRIFLUOROMETHYL-PHENYL)-PROPIONIC ACID

C10H9ClF3NO2 (267.027388)

Thiabendazole Hypophosphite

C10H10N3O2PS (267.02313300000003)

2-Chloro-N-(4-chlorophenethyl)propan-1-amine hydrochloride

C11H16Cl3N (267.03482660000003)

3-HYDROXY-2-(4-NITROPHENYL)-1H-INDEN-1-ONE

C15H9NO4 (267.0531554)

2-(4-Bromophenyl)-1-(1-pyrrolidinyl)ethanone

C12H14BrNO (267.02586940000003)

(4-(dimethylamino)pyridin-3-yl)(2-thioxothiazolidin-3-yl)methanone

C11H13N3OS2 (267.0500008)

2-(4-NITROPHENYL)IMIDAZO[1,2-A]PYRIDINE-3-CARBOXALDEHYDE

C14H9N3O3 (267.0643884)

2-amino-2-deoxyinosine

C10H13N5O4 (267.09674980000005)

5-Benzyl-4-phenyl-4H-1,2,4-triazol-3-ylhydrosulfide

C15H13N3S (267.0830138)

N-(3H-BENZOIMIDAZOL-4-YL)-4-METHOXY-BENZAMIDE

C15H13N3O2 (267.1007718)

1H-Indole-2-carboxylicacid, 3-(4-methoxyphenyl)-

C16H13NO3 (267.0895388)

1-(4-METHOXY-PHENYL)-1H-INDOLE-2-CARBOXYLIC ACID

C16H13NO3 (267.0895388)

(3R,4R)-N-CBZ-3,4-DIFLUOROPYRROLIDINE

C14H18ClNO2 (267.1025998)

2-deoxyisoguanosine

C10H13N5O4 (267.09674980000005)

2-(2-AMINOPHENYL)-5-(3-METHOXYPHENYL)-1,3,4-OXADIAZOLE

C15H13N3O2 (267.1007718)

4-(4-METHYLPHENYL)-5-PHENYL-4H-1,2,4-TRIAZOLE-3-THIOL

C15H13N3S (267.0830138)

1-Amino-9,10-dioxo-9,10-dihydro-2-anthracenecarboxylic acid

C15H9NO4 (267.0531554)

3-N-MALEIMIDOBENZOHYDRAZIDE-HCL

C11H10ClN3O3 (267.041066)

1-ETHYL-2,3,3-TRIMETHYL-3H-INDOL-1-IUM-5-SULFONATE

C13H17NO3S (267.0929092)

Methyl 4-(3-chlorophenyl)-2-methylthiazole-5-carboxylate

C12H10ClNO2S (267.01207500000004)

5,7-Dihydro-2-(methylthio)-6H-pyrrolo[3,4-d]pyrimidine-6-carboxylic acid 1,1-dimethylethyl ester

C12H17N3O2S (267.1041422)

(3R)-3-Benzyl-7a-(difluoromethyl)tetrahydropyrrolo[2,1-b]oxa-zol-5(6H)-one

C14H15F2NO2 (267.1070794)

Urea, N-[4-(methylthio)phenyl]-N-4-morpholinyl- (9CI)

C12H17N3O2S (267.1041422)

ethyl 5-amino-1-(2,5-difluorophenyl)pyrazole-4-carboxylate

C12H11F2N3O2 (267.081929)

2-(4-fluoro-phenyl)-quinoline-4-carboxylic acid

C16H10FNO2 (267.06955320000003)

4-CHLORO-9-METHYL-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE

C14H15Cl2N (267.058149)

S-(2,3,4-Trihydroxybutyl)mercapturic Acid

C9H17NO6S (267.07765420000004)

4-[4-(chloromethyl)piperidin-1-yl]thieno[3,2-d]pyrimidine

C12H14ClN3S (267.0596914)

4-METHOXY-2-(TRIFLUOROMETHYL)-[1,1-BIPHENYL]-4-AMINE

C14H12F3NO (267.0870938)

ethyl 5-amino-1-(2,4-difluorophenyl)pyrazole-4-carboxylate

C12H11F2N3O2 (267.081929)

3-(2-PYRIMIDINYLOXY)BENZENECARBOXYLIC ACID

C15H13N3O2 (267.1007718)

(3S,4S)-3,4-BIS[[(1,1-DIMETHYLETHYL)DIMETHYLSILYL]OXY]-1-(PHENYLMETHYL)-PYRROLIDINE

C14H18ClNO2 (267.1025998)

(R)-fenfluramine

C12H17ClF3N (267.10015480000004)

N,N-(7-HYDROXYTHIAZOLO[4,5-D]PYRIMIDINE-2,5-DIYL)DIACETAMIDE

C9H9N5O3S (267.0426084)

6-Benzyloxy-1h-indole-2-boronic acid

C15H14BNO3 (267.1066684)

4-methyl-N-(trifluoromethylsulfonyl)benzamide

C9H8F3NO3S (267.01769740000003)

DIMETHYL (4-NITROBENZYL)MALONATE

C12H13NO6 (267.0742838)

2-[carboxymethyl(phenylmethoxycarbonyl)amino]acetic acid

C12H13NO6 (267.0742838)

N2-Acetyl-9-[(2-hydroxyethoxy)methyl]guanine

C10H13N5O4 (267.09674980000005)

2,3-DIHYDROSPIRO[INDENE-1,4-PIPERIDINE]-3-CARBOXYLIC ACID HYDROCHLORIDE

C14H18ClNO2 (267.1025998)

(1-methylsulfonylpiperidin-4-yl)-phenylmethanone

C13H17NO3S (267.0929092)

1-(2-chloroacetyl)-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid methyl ester

C12H10ClNO4 (267.029833)

2-[(7-CHLOROQUINOLIN-4-YL)THIO]ACETOHYDRAZIDE

C11H10ClN3OS (267.023308)

BIO-FARMA BF002424

C15H13N3O2 (267.1007718)

(4-CHLORO-3-(PIPERIDINE-1-CARBONYL)PHENYL)BORONIC ACID

C12H15BClNO3 (267.083346)

3-CHLORO-4-(PIPERIDINE-1-CARBONYL)PHENYLBORONIC ACID

C12H15BClNO3 (267.083346)

(3-CHLORO-4-(CYCLOPENTYLCARBAMOYL)PHENYL)BORONIC ACID

C12H15BClNO3 (267.083346)

(3-Chloro-5-(piperidine-1-carbonyl)phenyl)boronic acid

C12H15BClNO3 (267.083346)

1-Acetyl-4-(2,4-difluorobenzoyl)piperidine

C14H15F2NO2 (267.1070794)

3-(1,3-dioxoisoindol-2-yl)benzoic acid

C15H9NO4 (267.0531554)

N-Cyclohexyl-2-iodoacetamide

C8H14INO (267.0120104)

1,2,4-Triazine,3-chloro-5,6-diphenyl-

C15H10ClN3 (267.056321)

1-(3-Chlorobenzoyl)piperidine-4-carboxylic acid

C13H14ClNO3 (267.06621640000003)

1-(4-CHLOROBENZYL)-1H-PYRAZOL-5-AMINEHYDROCHLORIDE

C13H14ClNO3 (267.06621640000003)

N-(4-Chlorophenyl)-2,6-difluorobenzamide

C13H8ClF2NO (267.0262452)

N-(4-Nitrophenyl)-L-glutamine

Alagebrium chloride

C13H14ClNOS (267.0484584)

C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent

formycin A

C10H13N5O4 (267.09674980000005)

D000970 - Antineoplastic Agents > D000903 - Antibiotics, Antineoplastic > D005573 - Formycins

PHENYL PHENYLPHOSPHORAMIDOCHLORIDATE

C12H11ClNO2P (267.0215906)

2-(fluoren-9-ylideneamino)oxypropanoic acid

C16H13NO3 (267.0895388)

1H-benzimidazol-2-ylmethyl 4-aminobenzoate

C15H13N3O2 (267.1007718)

2-Chloro-4-trimethylsilanylethynyl-nicotinic acid methyl ester

C12H14ClNO2Si (267.0482294)

4-Bromo-N-cyclopentylbenzamide

C12H14BrNO (267.02586940000003)

3-Bromo-N-cyclopentylbenzamide

C12H14BrNO (267.02586940000003)

Propenidazole

C11H13N3O5 (267.0855168)

G - Genito urinary system and sex hormones > G01 - Gynecological antiinfectives and antiseptics > G01A - Antiinfectives and antiseptics, excl. combinations with corticosteroids > G01AF - Imidazole derivatives P - Antiparasitic products, insecticides and repellents > P01 - Antiprotozoals > P01A - Agents against amoebiasis and other protozoal diseases > P01AB - Nitroimidazole derivatives C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent

2-(5-(trifluoromethyl)pyridin-2-yl)benzoic acid

C13H8F3NO2 (267.0507104)

1-(4-methylphenyl)-3-(3-nitrophenyl)prop-2-en-1-one

C16H13NO3 (267.0895388)

2-Naphthalenecarboxylicacid, 4-(aminosulfonyl)-1-hydroxy-

C11H9NO5S (267.0201424)

TERT-BUTYL 2-FORMYL-6,7-DIHYDROTHIENO[3,2-C]PYRIDINE-5(4H)-CARBOXYLATE

C13H17NO3S (267.0929092)

CHEMBRDG-BB 5259339

C12H14BrNO (267.02586940000003)

1-[3-(4-Bromophenyl)propyl]pyrrolidine

C13H18BrN (267.0622528)

1-benzyl-3-bromopiperidin-4-one

C12H14BrNO (267.02586940000003)

2-(m-Aminoanilino)-4-phenyl-thiazole

C15H13N3S (267.0830138)

2-(p-Aminoanilino)-4-phenyl-thiazole

C15H13N3S (267.0830138)

Zonisamide N,N-Dimethylformimidamide

C11H13N3O3S (267.06775880000004)

8-fluoro-2-phenylquinoline-4-carboxylic acid

C16H10FNO2 (267.06955320000003)

8-oxo-7-phenylpyrido[2,3-d]pyridazine-5-carboxylic acid

C14H9N3O3 (267.0643884)

fenfluramine hydrochloride

5-[2-(Trifluoromethoxy)phenyl]-3-pyridinecarbaldehyde

C13H8F3NO2 (267.0507104)

ETHYL 4-CHLORO-3-TRIFLUOROMETHYLCARBANILATE

C10H9ClF3NO2 (267.027388)

Rasagiline mesylate

3-ACETYL-2,7-DIMETHYL-5H-CHROMENO[2,3-B]PYRIDIN-5-ONE

C16H13NO3 (267.0895388)

3-(TRIFLUOROMETHYL)-N-(2,2-DIMETHOXYETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE

C9H12F3N3O3 (267.08307179999997)

L-Adenosine

4-([(2-FURYLMETHYL)AMINO]METHYL)BENZOIC ACID HYDROCHLORIDE

C13H14ClNO3 (267.06621640000003)

Morpholine,2-[3-(trifluoromethyl)phenyl]-, hydrochloride (1:1)

C11H13ClF3NO (267.0637714)

4-(6-CHLORO-2-(TRIFLUOROMETHYL)PYRIMIDIN-4-YL)MORPHOLINE

C9H9ClF3N3O (267.03862100000003)

3-(2-bromoethyl)-5-methoxy-1-methylindole

C12H14BrNO (267.02586940000003)

Sulfatroxazole

4-Amino-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide

C11H13N3O3S (267.06775880000004)

C254 - Anti-Infective Agent > C29739 - Sulfonamide Anti-Infective Agent D000890 - Anti-Infective Agents > D013424 - Sulfanilamides

4-Fluoro-3-nitrophenylboronic acid pinacol ester

C12H15BFNO4 (267.1078112)

4-(3,4-dichlorophenyl)-5,6-dimethylpyrimidin-2-amine

C12H11Cl2N3 (267.03299860000004)

(3-BROMOPHENYL)(PIPERIDIN-1-YL)METHANONE

C12H14BrNO (267.02586940000003)

Z-D-Asp-OH

C12H13NO6 (267.0742838)

1-(2-ethyl-4-hydroxy-1,1-dioxo-1λ6,2-benzothiazin-3-yl)ethanone

C12H13NO4S (267.05652580000003)

2-AMINO-9-((2R,4S,5S)-4-HYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-3H-PURIN-6(9H)-ONE

C10H13N5O4 (267.09674980000005)

N-[(Benzyloxy)carbonyl]aspartic acid

C12H13NO6 (267.0742838)

ETHYL 4-CHLORO-5-ISOPROPYLPYRROLO[2,1-F][1,2,4]TRIAZINE-6-CARBOXYLATE

C12H14ClN3O2 (267.0774494)

9-(2-ACETOXYETHOXYMETHYL)GUANINE

C10H13N5O4 (267.09674980000005)

3-(carbamoylamino)-5-thiophen-3-ylthiophene-2-carboxamide

C10H9N3O2S2 (267.0136174)

6'-Chloro-3,2:5,3'-terpyridine

6"-Chloro-3,2:5,3"-terpyridine

3-C-Ethynylcytidine

C11H13N3O5 (267.0855168)

C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite Ethynylcytidine (ECyD), a nucleoside analog and a potent inhibitor of RNA synthesis, inhibits RNA polymerases I, II and II. Ethynylcytidine has robust antitumor activity in a wide range of models of cancer[1][2][3]. Ethynylcytidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

9-beta-D-Xylofuranosyladenine

C10H13N5O4 (267.09674980000005)

9-(β-D-Xylofuranosyl)adenine is an adenosine analog. Adenosine analogs mostly act as smooth muscle vasodilators and have also been shown to inhibit cancer progression. Its popular products are adenosine phosphate, Acadesine (HY-13417), Clofarabine (HY-A0005), Fludarabine phosphate (HY-B0028) and Vidarabine (HY-B0277)[1].

9-Deazainosine

C11H13N3O5 (267.0855168)

Aladorian

C12H13NO4S (267.05652580000003)

C78274 - Agent Affecting Cardiovascular System

beta-Neuraminic acid

C9H17NO8 (267.0954122)

2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

C10H13N5O4 (267.09674980000005)

3-[(2-Benzyl-3-sulfanylpropanoyl)amino]propanoic acid

C13H17NO3S (267.0929092)

D004791 - Enzyme Inhibitors

1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-pyrimidine-2,4-dione

C10H13N5O4 (267.09674980000005)

N~5~-(4-nitrophenyl)glutamine

C11H13N3O5 (267.0855168)

2-(3-Nitrophenyl)-5-phenyl-1,3,4-oxadiazole

C14H9N3O3 (267.0643884)

2-(1,5-dimethyl-1H-pyrazol-4-yl)quinoline-4-carboxylic acid

C15H13N3O2 (267.1007718)

2-(1-ethyl-1H-pyrazol-4-yl)quinoline-4-carboxylic acid

C15H13N3O2 (267.1007718)

Benzyl alcohol, o-chloro-alpha-((isopropylamino)methyl)-, hydrochloride, monohydrate

2-O-(alpha-D-glucopyranosyl)-D-glycerate

C9H15O9- (267.071604)

3-deoxy-D-glycero-beta-D-galacto-nonulosonate

C9H15O9- (267.071604)

A carbohydrate acid derivative anion obtained by deprotonation of the carboxy group of 3-deoxy-D-glycero-beta-D-galacto-nonulosonic acid

2-(alpha-D-mannosyl)-D-glycerate

1-amino-3-[3-(2-sulfanylidene-3H-1,3,4-oxadiazol-5-yl)phenyl]thiourea

C9H9N5OS2 (267.0248504)

1-[2-[(4-Chlorophenoxy)methyl]-4-thiazolyl]ethanone

C12H10ClNO2S (267.01207500000004)

Formononetin(1-)

C16H11O4- (267.0657306)

A flavonoid oxoanion that is the conjugate base of formononetin, obtained by deprotonation of the 7-hydroxy group. Major microspecies at pH 7.3 (according to Marvin v 6.2.0.).

N-(phenylmethyl)-4-(3-pyridinyl)-2-thiazolamine

C15H13N3S (267.0830138)

4-butyl-3-(5-ethyl-3-thiophenyl)-1H-1,2,4-triazole-5-thione

C12H17N3S2 (267.0863842)

(2R,4R,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

C10H13N5O4 (267.09674980000005)

N-(4-methoxyphenyl)-1-benzofuran-2-carboxamide

C16H13NO3 (267.0895388)

Dexfenfluramine HCl

C12H17ClF3N (267.10015480000004)

N-(1,3-benzodioxol-5-ylmethyl)-1H-benzimidazol-2-amine

C15H13N3O2 (267.1007718)

(4S,5R,6R,7S,8R)-5-amino-4,6,7,8,9-pentahydroxy-2-oxononanoic acid

C9H17NO8 (267.0954122)

3-Amino-4-(2-aminoanilino)-1-benzopyran-2-one

C15H13N3O2 (267.1007718)

N-(1-naphthalenylmethyl)-2-thiophenecarboxamide

C16H13NOS (267.0717808)

5-hydroxy-8-methoxy-4-phenylisoquinolin-1(2H)-one

7-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrrolo[2,3-d]pyrimidine-2,4-dione

C11H13N3O5 (267.0855168)

Neuraminic acid

C9H17NO8 (267.0954122)

S-(5-Deoxy-D-ribos-5-yl)-L-homocysteine

C9H17NO6S (267.07765420000004)

Prinomide

C15H13N3O2 (267.1007718)

C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic

N-(1-Deoxy-1-fructosyl)serine

C9H17NO8 (267.0954122)

O-(alpha-D-mannosyl)-L-serine

C9H17NO8 (267.0954122)

1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine

C8H14NO7P (267.0507864)

A glycerophosphoethanolamine compound having an alk-1-enyl substituent at the 1-position and an acyl substituent at the 2-position.

S-(5-deoxy-beta-D-ribos-5-yl)-L-homocysteine

C9H17NO6S (267.07765420000004)

An S-(5-deoxy-D-ribos-5-yl)-L-homocysteine in which the anomeric centre has beta-configuration.

S-(5-deoxy-D-ribos-5-yl)-L-homocysteine zwitterion

C9H17NO6S (267.07765420000004)

Zwitterionic form of S-(5-deoxy-D-ribos-5-yl)-L-homocysteine arising from transfer of a proton from the carboxy to the amino group; major species at pH 7.3.

nitrososulfamethoxazole

C10H9N3O4S (267.0313754)

A sulfonamide compound having a 4-nitrosophenyl group attached to the sulfur atom and a 1,2-oxazol-3-yl group attached to the nitrogen atom.

Adenine arabinoside

C10H13N5O4 (267.09674980000005)

A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.

Oxodeoxyadenosine

C10H13N5O4 (267.09674980000005)

Phenylacetylmethionine

C13H17NO3S (267.0929092)

Aminooxo(dioxoprolyl)dihydroxypteridine

C9H9N5O5 (267.0603664)

IMM-01

C12H17N3O2S (267.1041422)

IMM-01 is a mammalian Diaphanous (mDia)-related formins agonist that inhibits DID-DAD (diaphanous inhibitory domain-diaphanous autoregulatory domain) binding with an IC50 of 140 nM. IMM-01 acts by disrupting the autoinhibitory bond between the DID and DAD domain and thus activates formins. IMM-01 shows anticancer effects[1].

4-(3-methoxyindole-1-carbonyl)phenol

C16H13NO3 (267.0895388)

2-[(4-hydroxyphenyl)formamido]pentanedioic acid

C12H13NO6 (267.0742838)

2-methyl-4,4-dioxo-n-phenyl-5,6-dihydro-1,4λ⁶-oxathiine-3-carboximidic acid

C12H13NO4S (267.05652580000003)

(3r,6s,8s)-6,8-dihydroxy-4,9-dioxa-2-azatricyclo[8.4.0.0³,⁸]tetradeca-1(10),11,13-triene-14-carboxylic acid

C12H13NO6 (267.0742838)

astone

C11H19Cl2NO2 (267.0792774)

{"Ingredient_id": "HBIN017208","Ingredient_name": "astone","Alias": "NA","Ingredient_formula": "C11H19Cl2NO2","Ingredient_Smile": "CC(C)NCC(C1=CC=CC=C1Cl)O.O.Cl","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "30631","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}